Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Abstract
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials. The systematic use of easily implemented measurement-based care procedures may have assisted in achieving these results.
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
research support
female
male
N.I.H.
Extramural
Depressive Disorder
Major / epidemiology
adolescent
middle aged
Comorbidity
Drug Administration Schedule
Comparative Study
Clinical Trial
Multicenter Study
dose-response relationship
drug
chronic disease
psychiatric status rating scales / statistics & numerical data
phase i
mental disorders / epidemiology
secondary prevention
madhukar h trivedi
ambulatory care
major / drug therapy*
a john rush
major / diagnosis
pmid:16390886
doi:10.1176/appi.ajp.163.1.28
star*d study team
citalopram / therapeutic use*
personality inventory
serotonin uptake inhibitors / therapeutic use*
Citation
ID:
120397
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
120397
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet
